 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Name:
|
Suritozole
|
|
Other Names:
|
MD 26,479
|
|
Development Status:
|
investigational in U.S.
|
|
FDA Phase:
|
Discontinued
|
|
Role in Alzheimer's Disease:
|
An inverse GABA agonist with cognitive enhancement
properties.
|
|
Companies:
|
Aventis Pharmaceuticals, Inc. (was Hoechst)
|
Robbins DK, Hutcheson SJ, Miller TD, Green VI, Bhargava
VO, Weir SJ. Pharmacokinetics of MDL 26479, a novel
benzodiazepine inverse agonist, in normal volunteers.
Biopharm Drug Dispos. 1997 May;18(4):325-34. Abstract
O'Dell DM, Hamm RJ. Chronic postinjury administration of
MDL 26,479 (Suritozole), a negative modulator at the GABAA
receptor, and cognitive impairment in rats following
traumatic brain injury. J Neurosurg. 1995 Nov;83(5):878-83. Abstract
Holley LA, Miller JA, Chmielewski PA, Dudchenko P, Sarter
M. Interactions between the effects of basal forebrain
lesions and chronic treatment with MDL 26,479 on learning
and markers of cholinergic transmission. Brain Res. 1993
May 7;610(2):181-93. Abstract
Miller JA, Dudley MW, Kehne JH, Sorensen SM, Kane JM. MDL
26,479: a potential cognition enhancer with benzodiazepine
inverse agonist-like properties. Br J Pharmacol. 1992
Sep;107(1):78-86. Abstract
Moran PM, Kane JM, Moser PC. Enhancement of working memory
performance in the rat by MDL 26,479, a novel compound
with activity at the GABAA receptor complex. Brain Res.
1992 Jan 8;569(1):156-8. Abstract
Holley LA, Dudchenko P, Sarter M. Attenuation of
muscarinic receptor blockade-induced impairment of spatial
delayed alternation performance by the triazole MDL 26,479.
Psychopharmacology (Berl). 1992;109(1-2):223-30. Abstract
|
|
|
|
|
Home
